Beam Therapeutics, Inc. (BEAM) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$24.90

From 52W high−34.20%

Volume2.26M

Market cap$2.58B

P/E (TTM)—

P/S (TTM)16.5x

Div yield—

Key dataSep 18, 2026

Open

$24.90

From 52W high

−34.20%

Volume

2.26M

Market cap

$2.58B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−27.7x

P/E (TTM)

—

RSI (14)

39.4

MomentumView details →

1D Return

+1.13%

YTD Return

−11.80%

SummaryUpdated Jun 1, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company founded in 2017 and based in Cambridge, Massachusetts. The company went public in February 2020 and has emerged as a leader in precision genetic medicine, specifically focusing on base editing technology to develop treatments for serious genetic diseases. Beam has built a comprehensive pipeline of experimental therapies targeting blood disorders, liver diseases, and other genetic conditions, with several programs advancing through clinical trials.

Ask drillr about Beam Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−27.7x

EV/Sales

10.7x

P/S (TTM)

16.5x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

18.93%

Net Margin

−54.75%

EBITDA Margin

−38.64%

ROE (TTM)

−8.00%

ROA (TTM)

−6.16%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

+158.88%

EPS YoY

+81.78%

FCF YoY

−4.84%

Revenue CAGR 3Y

+31.88%

EPS CAGR 3Y

+82.31%

EBITDA YoY

+84.78%

MomentumView details →

1D Return

+1.13%

YTD Return

−11.80%

1Y Return

+0.53%

RSI (14)

39.4

vs 50D SMA

−10.72%

vs 200D SMA

−14.47%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

14.57x

Quick Ratio

14.57x

Div Yield

—

Div Rate

—

Div Growth 1Y

−75.00%

EarningsView details →

EPS (Actual)

−$1.18

EPS Surprise

−6.31%

Beats (12Q)

4/12

Next Q EPS Est

−$1.15

Avg Surprise (4Q)

17.00%

Rev Surprise

−97.01%

Financials snapshotView financials →

Revenue (TTM)

156.03M

Net Income (TTM)

−85.43M

Op. CF (TTM)

−359.38M

Next earningsNov 3, 2026 →

Latest newsMore news →

Beam Therapeutics appointed Eric Foster as chief commercial officer.18d ago

Beam Therapeutics Inc. reported a second-quarter loss of $1.18 per share, missing the Zacks Consensus Estimate of a loss of $1.00 per share.47d ago

Similar companies

Pharvaris N.V.PHVS Braveheart Bio, Inc.BRVE Nurix Therapeutics, Inc.NRIX Structure Therapeutics Inc.GPCR Viridian Therapeutics, Inc.VRDN Clover Biopharmaceuticals, Ltd.02197.HK Find similar companies →

Latest newsMore news →

Beam Therapeutics appointed Eric Foster as chief commercial officer.18d ago Beam Therapeutics Inc. reported a second-quarter loss of $1.18 per share, missing the Zacks Consensus Estimate of a loss of $1.00 per share.47d ago